Time Restricted Eating (TRE) Among Native Hawaiian/Pacific Islander Women at Risk for Endometrial Cancer (TIMESPAN)

Feasibility and Acceptability of Time Restricted Eating (TRE) Among Native Hawaiian/Pacific Islander Women at Risk for Endometrial Cancer

The long-term goal of this study is to determine the efficacy of time restricted eating (TRE) for improving metabolic health and preventing endometrial cancer. The primary objective of the protocol is to conduct a 14-week two-arm randomized crossover trial of a dietary intervention to evaluate the feasibility, fidelity and preliminary acceptability of a TRE intervention among Native Hawaiian/Pacific Islander women at risk for developing endometrial cancer, and to provide proof of principle that TRE can improve metabolic health in this population.

Study Overview

• Status: Completed
• Conditions: Endometrial Neoplasms
• Intervention / Treatment: Behavioral: Time Restricted Eating (TRE) Schedule

Detailed Description

Enrollment: The study includes two phases. Phase 1 includes focus groups among 30 Native Hawaiian/Pacific Islander women at risk of endometrial cancer. Focus groups will determine sociocultural influences on (i) dietary behavior including meal timing; (ii) dietary preferences; (iii) proposed meal plans and intervention design; (iv) perceptions of weight loss and body image. In the second study phase, the study team will recruit 10 Pacific Islander women to participate in a 14-week randomized dietary crossover study. Each woman will participate in both intervention arms and act as her own control.

Focus Group: To accomplish all aspects of Aim 1 of this study, the study team will recruit 30 Pacific Islander women at risk for endometrial cancer to conduct virtual focus groups. These focus groups will take place via private videoconference, like Zoom, and a language translator will be provided, as necessary. The focus groups will be attended by a Native Hawaiian/Pacific Islander Community Expert. Questions will be designed to understand sociocultural influences on dietary behavior (questions on social eating, meal timing, and dietary preferences, soliciting feedback on study intervention delivery design, and perceptions of weight loss and body image). An icebreaker will be conducted prior to formal questioning. Sessions will be audio-recorded on the videoconference and an additional device, transcribed verbatim, and checked for accuracy. Two additional team members will be present as note takers. Our Community Expert will be present to help facilitate the session. Questions will be provided at the beginning of the session to ensure cultural sensitivity.

Dietary Intervention: The dietary intervention includes 5 study visits, and features a baseline visit, 2-week run-in period, 4-week control diet schedule, 4-week washout period, and a 4-week, 8 to 10-hour Time Restricted Eating (TRE) protocol (8 to 10-hour feeding and 14 to 16-hour fasting periods). A follow-up questionnaire will be mailed 6-months post- intervention. For the control schedule, women will receive frozen lunch and dinner meals and a standardized breakfast and snacks menu. All meals and the breakfast/snack menu will be designed to be culturally competent with feedback from the focus groups, and meal plans will be individualized to meet weight maintenance energy requirements. For the TRE schedule, women will receive prepared frozen lunch and dinner meals as per the control schedule, but will be asked to consume daily meals, snacks, and calorie-containing beverages within an 8 to 10-hour period that fits their schedule. They will be asked to maintain their regular sleep and physical activity schedule. The fasting period will ramp up during the first week (Days 1-3, 12-14 h per day, Days 4-6, 14-16 h per day, Days 7+, 16 h per day). Women will be asked to schedule the eating period at the same time each day. All meals (control and TRE) will be provided by the Metabolic Kitchen located at the University of Utah.

Visit 1: During the baseline visit, a coordinator will obtain consent from the participant, and they will be asked to compete questionnaires asking about clinical and demographic factors, chronotype, and physical activity, and various anthropometric measurements will be taken. Following the baseline visit, participants will undergo a 2-week run-in period. During this time, the goal is to record women's usual times of eating episodes and appetite while following their habitual diet.

Visit 2: Women will provide fasting blood and stool samples, and anthropometric measurements will be taken. Following visit 2, participants will undergo the control or TRE schedule for 4 weeks.

Visit 3: After 4 weeks, participants will undergo visit 3 and will be asked to provide fasting blood and stool samples, and anthropometric measures will be taken. Following visit 3, participants will undergo a 4-week washout period, where women are able to return to their usual lifestyle.

Visit 4: Visit 4 will occur after the 4-week washout period, and will include a telephone consultation to discuss the next study phase and schedule meal provision. For the following 4-weeks, participants will then undergo the opposite feeding schedule (either control or TRE).

Visit 5: During the final visit, women will provide fasting blood and stool samples, and anthropometric measures will be taken.

During the run-in period, the TRE phase and the control phase, participants will record timing of eating episodes using the MyCircadian Clock phone app, complete 3 x 24-hour diet recalls, a single physical activity recall, and 7-days of sleep and physical activity will be objectively measured using an Actiwatch device. Hunger and satiety will be evaluated at random through the MyCircadian Clock phone app.

A study exit interview will be conducted via Zoom conference call to debrief on the intervention and obtain detailed information on acceptability of the protocol. Approximately 6-months after the end of the intervention period, women will complete a mailed follow-up questionnaire.

• Study Type: Interventional
• Enrollment (Actual): 17
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Mary Playdon, PhD, MPH; Phone Number: (801) 213-6264; Email: mary.playdon@hci.utah.edu

Study Locations

• United States
  • Utah
    • Salt Lake City, Utah, United States, 84112
      • Huntsman Cancer Institute

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

All Aims:

• Native Hawaiian/Pacific Islander females aged 18 years or older
• Overweight or obese (BMI>25kg/m2) OR have a history of non-insulin dependent diabetes OR have a history of complex atypical endometrial hyperplasia
• Have a working cell phone that can download an App
• Able to use cell phone during day (e.g. at work)
• Not a night shift worker

Applicable Only to Aims 2 & 3:

• Able to attend study visits at the Huntsman Cancer Institute Center for HOPE

Exclusion Criteria:

All Aims:

• Unable to provide informed consent

Applicable Only to Aims 2 & 3:

• Necessity of a special diet that precludes adjustment of meal timing and/or macronutrient content
• Have a history of insulin dependent diabetes
• Have a history of hysterectomy

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Time Restricted Eating (TRE) Schedule; For 8 weeks out of the 14-week randomized dietary crossover study, women will receive prepared frozen lunch and dinner meals as per the control schedule, but will be asked to consume daily meals, snacks, and calories-containing beverages within an 8 to 10-hour period that fits their schedule. The fasting period will ramp up during the first week (Days 1-3, 12-14 h per day, Days 4-6, 14-16 h per day, Days 7+, 16 h per day).	Behavioral: Time Restricted Eating (TRE) Schedule; [See arm/group descriptions]
No Intervention: Control Schedule; For 4 weeks out of the 14-week randomized dietary crossover study, women will receive prepared frozen lunch and dinner meals, and a standardized breakfast and snacks menu. All meals and snacks will be culturally competent, and meal plans will be individualized to meet weight maintenance energy requirements.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Proportion of Women Referred that are Consented	Feasibility of the TRE intervention will be measured by calculating a proportion (%) of women who were referred that were consented into the study. The study will be considered feasible if > 70% of participants are consented and retained.	From baseline to Visit 5 (Week 14)
Attrition as a Function of Time	Number of participants who withdraw throughout the course of the study.	From baseline to Visit 5 (Week 14)
Percent of Scheduled Assessments Completed	Feasibility of the TRE intervention will be assessed by calculating a percentage of scheduled biospecimen collection and questionnaires completed.	From baseline to Visit 5 (Week 14)
Number of TRE-Adherent Days per Week	Feasibility of the TRE intervention will be measured by calculating the number of TRE-adherent days per week. Participants will be considered adherent if they fasted between 14-18 hours per day during the TRE phase according to a mealtime log. The study will be considered feasible if women adhere to the TRE protocol on average 5 days per week.	From baseline to Visit 5 (Week 14)
Percentage of Meals Delivered On Schedule	Feasibility of the TRE intervention will be measured by calculating a percentage of meals delivered on schedule.	From baseline to Visit 5 (Week 14)
Fidelity of Time Restricted Eating (TRE) Intervention	Fidelity will be evaluated as a percentage of protocol checklist items delivered as intended with a goal of 90%.	From baseline to Visit 5 (Week 14)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in blood pressure assessed via electronic blood pressure monitor	Blood pressure will be taken using an electronic blood pressure monitor.	Baseline (Visit 1), Visit 2 (Week 2), Visit 3 (Week 6), Visit 5 (Week 14)
Change in waist circumference assessed via measuring tape	Waist circumference will be measured using a measuring tape.	Baseline (Visit 1), Visit 2 (Week 2), Visit 3 (Week 6), Visit 5 (Week 14)
Change in BMI assessed via height and weight	Participants' height and weight will be taken and used to calculate BMI.	Baseline (Visit 1), Visit 2 (Week 2), Visit 3 (Week 6), Visit 5 (Week 14)
Change in fasting blood glucose assessed via blood draw	A small sample of blood will be taken from participants at designated study visits.	Visit 2 (Week 2), Visit 3 (Week 6), Visit 5 (Week 14)
Change in HOMA-IR assessed via blood draw	A small sample of blood will be taken from participants at designated study visits.	Visit 2 (Week 2), Visit 3 (Week 6), Visit 5 (Week 14)
Change in c-peptide assessed via blood draw	A small sample of blood will be taken from participants at designated study visits.	Visit 2 (Week 2), Visit 3 (Week 6), Visit 5 (Week 14)
Change in triglycerides assessed via blood draw	A small sample of blood will be taken from participants at designated study visits.	Visit 2 (Week 2), Visit 3 (Week 6), Visit 5 (Week 14)
Change in HDL-cholesterol assessed via blood draw	A small sample of blood will be taken from participants at designated study visits.	Visit 2 (Week 2), Visit 3 (Week 6), Visit 5 (Week 14)
Change in high sensitivity C-reactive protein assessed via blood draw	A small sample of blood will be taken from participants at designated study visits.	Visit 2 (Week 2), Visit 3 (Week 6), Visit 5 (Week 14)

Collaborators and Investigators

• Sponsor: University of Utah
• Collaborators: National Center for Advancing Translational Sciences (NCATS)
• Investigators: Principal Investigator: Mary Playdon, PhD, MPH, University of Utah

Study record dates

Study Major Dates

• Study Start (Actual): February 18, 2021
• Primary Completion (Actual): June 10, 2022
• Study Completion (Actual): September 30, 2022

Study Registration Dates

• First Submitted: February 8, 2021
• First Submitted That Met QC Criteria: February 18, 2021
• First Posted (Actual): February 21, 2021

Study Record Updates

• Last Update Posted (Actual): November 30, 2023
• Last Update Submitted That Met QC Criteria: November 28, 2023
• Last Verified: November 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Uterine Neoplasms; Genital Neoplasms, Female; Uterine Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Diseases; Genital Diseases, Female; Endometrial Neoplasms
• Other Study ID Numbers: IRB_00127142; UL1TR002538 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No